Skip to main content

Cardio-Oncology and Immunotherapy

Edited by:

Steven Lipshultz, MD, University at Buffalo, United States of America
Joseph Carver, MD, University of Pennsylvania and Abramson Cancer Center, United States of America
Giorgio Minotti, MD, University and Fondazione Policlinico Campus Bio-Medico, Italy

Submission Status: Open   |   Submission Deadline: 30 September 2025


Cardio-Oncology is calling for submissions to our Collection on 'Cardio-Oncology and Immunotherapy.' This Collection aims to explore the intersection of cardiovascular health and cancer immunotherapy, a rapidly growing field as novel treatments like immune checkpoint inhibitors and CAR T-cell therapies become more prevalent.

About the Collection

Cardio-Oncology is calling for submissions to our Collection on 'Cardio-Oncology and Immunotherapy.' This Collection aims to explore the intersection of cardiovascular health and cancer immunotherapy, a rapidly growing field as novel treatments like immune checkpoint inhibitors and CAR T-cell therapies become more prevalent. While these therapies offer promising cancer outcomes, they can pose significant cardiovascular risks, including myocarditis, arrhythmias, and heart failure. We welcome original research, reviews, and clinical studies that shed light on the cardiovascular effects of immunotherapy, mechanisms of toxicity, early detection, and management strategies.

Submissions are encouraged on the following topics:

  • Cardiovascular toxicities of immunotherapy
  • Mechanisms of immunotherapy-induced cardiotoxicity
  • Diagnostic and predictive biomarkers
  • Imaging advancements 
  • Management and prevention of cardiotoxicity
  • Risk stratification and patient monitoring
  • Long-term cardiovascular outcomes in cancer survivors
  • Preclinical models for cardio-oncology research Integrative approaches in cardio-oncology

Image credit: © freshidea / Stock.adobe.com

  1. Dexrazoxane, a putative iron chelator, is effective in preventing doxorubicin-induced cardiotoxicity. However, dexrazoxane is also a catalytic inhibitor of topoisomerase 2b (Top2b), a key mediator of doxorubic...

    Authors: Hui-Ming Chang, Jinn-Yuan Hsu, Chul Ahn and Edward T. H. Yeh
    Citation: Cardio-Oncology 2025 11:42
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of Research articles and Reviews. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Cardio-Oncology and Immunotherapy" under the “Details” tab during the submission stage. Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.